Starling Oncology (STLNW) Income towards Parent Company (2020 - 2026)

Starling Oncology (STLNW) has reported Income towards Parent Company for 7 consecutive years, with -$9.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income towards Parent Company rose 42.45% year-over-year to -$9.8 million; the trailing twelve-month figure through Jun 2026 stood at -$36.3 million (up 44.92% YoY), and the FY2025 full-year result was -$60.6 million, up 6.27% from the prior year.
• Income towards Parent Company slipped to -$9.8 million in Q2 2026 per STLNW's latest filing, from -$2.5 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $19.3 million in Q1 2022 and bottomed at -$30.0 million in Q1 2023.
• Historically, Income towards Parent Company has averaged -$12.2 million across 5 years, with a median of -$15.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Income towards Parent Company jumped 2036.35% in 2022, then tumbled 551.42% in 2023.
• Over 5 years, Income towards Parent Company stood at -$11.0 million in 2022, then slumped by 70.38% to -$18.8 million in 2023, then gained by 29.71% to -$13.2 million in 2024, then soared by 43.04% to -$7.5 million in 2025, then tumbled by 30.38% to -$9.8 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$9.8 million, -$2.5 million, and -$7.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.